How Oral Octreotide Capsules Replace Monthly Injections for Acromegaly
The TPE technology enables oral delivery of octreotide for acromegaly, achieving therapeutic levels despite only 0.7% oral bioavailability, offering patients a convenient alternative to monthly depot injections.
Quick Facts
What This Study Found
Oral octreotide using TPE technology achieved therapeutic endpoints in Phase III trials with ~0.7% relative oral bioavailability, requiring 20 mg capsules compared to 0.1 mg subcutaneous injections.
Key Numbers
20 mg capsule; 0.7% bioavailability; 200x subcutaneous dose; 2 Phase III trials; FDA approved 2020
How They Did This
Technological evaluation reviewing the TPE platform, preclinical data, Phase I pharmacokinetics, and Phase III clinical trial results for oral octreotide (MYCAPSSA).
Why This Research Matters
Successfully delivering a peptide drug orally is a major pharmaceutical achievement. This technology demonstrates that even with very low oral bioavailability, convenient oral peptide formulations can be clinically viable, opening doors for other peptide drugs.
The Bigger Picture
The oral delivery of peptide drugs has been a holy grail of pharmaceutical science. Following oral semaglutide for diabetes (2019), oral octreotide for acromegaly (2020) represents the second major milestone proving that selected peptides can be made orally available with the right formulation technology.
What This Study Doesn't Tell Us
Very low oral bioavailability (0.7%) means most of the drug is not absorbed. Requires high oral doses. The technology may not be applicable to all peptides. Patient adherence to twice-daily dosing versus monthly injections has trade-offs.
Questions This Raises
- ?Could TPE technology be applied to deliver other therapeutic peptides orally?
- ?How does long-term oral octreotide compare to injectable formulations in real-world outcomes?
- ?Can formulation improvements increase the oral bioavailability beyond 0.7%?
Trust & Context
- Key Stat:
- 0.7% oral bioavailability Still sufficient for therapeutic efficacy in Phase III trials, requiring 200x the injectable dose
- Evidence Grade:
- Technological review of an FDA-approved product with Phase III clinical trial support. High-quality evidence for the specific application.
- Study Age:
- Published in 2021, shortly after FDA approval of MYCAPSSA in 2020.
- Original Title:
- Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation.
- Published In:
- Expert opinion on drug delivery, 18(10), 1501-1512 (2021)
- Authors:
- Brayden, David J(4), Maher, Sam(2)
- Database ID:
- RPEP-05291
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How can a peptide drug be taken as a pill?
The TPE (Transient Permeation Enhancer) technology uses an oily formulation with special excipients that temporarily open the tight junctions between intestinal cells, allowing the octreotide peptide to pass through into the bloodstream. Only about 0.7% gets absorbed, so the oral dose is much higher than the injectable version.
Is oral octreotide as effective as the injectable version?
Phase III clinical trials showed that oral octreotide capsules met the same primary efficacy endpoints as injectable formulations for controlling acromegaly. Many patients prefer the convenience of twice-daily pills over monthly depot injections.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05291APA
Brayden, David J; Maher, Sam. (2021). Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation.. Expert opinion on drug delivery, 18(10), 1501-1512. https://doi.org/10.1080/17425247.2021.1942838
MLA
Brayden, David J, et al. "Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation.." Expert opinion on drug delivery, 2021. https://doi.org/10.1080/17425247.2021.1942838
RethinkPeptides
RethinkPeptides Research Database. "Transient Permeation Enhancer® (TPE®) technology for oral de..." RPEP-05291. Retrieved from https://rethinkpeptides.com/research/brayden-2021-transient-permeation-enhancer-tpe
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.